Klaus Metzeler

Professor of Translational Hematology

Leipzig University

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Klaus Metzeler is a researcher in Translational Hematology at the University of Leipzig, Germany. His recent work focuses on clonal hematopoiesis and its implications in acute myeloid leukemia (AML) and related conditions, including the prognostic impacts of various genetic mutations and responses to treatment. He has contributed to significant findings on the outcomes of patients undergoing allogeneic hematopoietic stem cell transplantation and the evolving classifications impacting prognosis in AML.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (10)

Madlen Jentzsch

GERMANY

View details

Petra Büttner

Head of Lab

Heart Center Leipzig at University of Leipzig

GERMANY

View details

Frederick Klauschen

Professor, Chair

Ludwig-Maximilians-Universität München

GERMANY

View details

Tobias Herold

University Hospital, LMU Munich

GERMANY

View details

Michael Menden

University of Melbourne

AUSTRALIA

View details

Janghee Woo

Winship Cancer Institute

UNITED STATES

View details

Marion Subklewe

LMU University Hospital

GERMANY

View details

Thomas Berg

Head of Division

Heart Center Leipzig at University of Leipzig

GERMANY

View details

Philipp Greif

University Hospital, LMU Munich

GERMANY

View details

Michael Cross

Head of Laboratory Research

Leipzig University

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Klaus Metzeler

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Letter to the Editor: Clonal hematopoiesis in MASLD-associated HCC: Variant burden may matter more than presence

Sex-associated differences in outcome of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation

Impact of Evolving WHO and ICC Classifications on Prognosis and Outcomes in AML Patients Undergoing Allogeneic Stem Cell Transplantation

Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study

Clonal hematopoiesis and its impact on the aging osteo-hematopoietic niche

Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation

Activation of distinct inflammatory pathways in subgroups of LR-MDS

Lessons learned: the first consecutive 1000 patients of the CCCMunich(LMU) Molecular Tumor Board

WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in mice

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy

Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles

Clonal Hematopoiesis Mutations Are Present in Atherosclerotic Lesions in Peripheral Artery Disease

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation

Clonal hematopoiesis and cardiovascular disease: deciphering interconnections

Collaborators (10)

Madlen Jentzsch

Petra Büttner

Frederick Klauschen

Tobias Herold

Michael Menden

Janghee Woo

Marion Subklewe

Thomas Berg

Philipp Greif

Michael Cross

Make your next move.